The renin-angiotensin-aldosterone system - New pathogenetic and therapeutic aspects Part 2. Aldosterone - important inductor of pathogenetic pathways damaging the cardiovascular system and kidneys;Układ renina-angiotensyna-aldosteron - Nowe aspekty patogenetyczne i lecznicze Czȩść 2. Aldosteron - ważny induktor szlaków patogenetycznych uszkadzaja̧cych układ sercowo-naczyniowy i nerki

Nadcisnienie Tetnicze

Volumn 11, Issue 4, 2007, Pages 357-363

  Hyla Klekot, Lidia ^a   Pulcer, Barbara ^a   Kokot, Franciszek ^b  

^a Chorzowskie Centrum Pediatrii I Onkologii W Chorzowie

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Aldosterone; Aldosterone inductor of important pathogenetic pathways; Aldosterone antagonists

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE; MINERALOCORTICOID RECEPTOR; PROTEIN MDM2; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR SYSTEM; DISEASE COURSE; DRUG EFFECT; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR FIBROSIS;

EID: 36849067361     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Schiffrin E.L. Wpływ aldosteronu na naczynia. Hypertension (wyd. polskie) 2006; 2: 1-7.
2. Dobrucki T., Januszewicz A., Sitkiewicz D., Januszewicz W. Aldosteron - hormon o nowym obliczu. Nadciśnienie Tȩtnicze 2003; 7: 271-279.
3. Cohn J.N., Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am. Cardiol. 2006; 97: 4-12.
4. Sato A., Hayashi K., Naruse M. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
5. Vecchio L.D., Procaccio M., Vigaro S. i wsp. Mechanism of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clin. Pract. Nephrol. 2007; 3: 42-49.
6. EpsteinM. Aldosterone as a mediator of progressive renal disease: pathogenic and clinical implication. Am. J. Kidney Dis. 2001; 37: 677-688.
7. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int. 2004; 4: 1-9.
8. Rump L.Ch. Secondary rise of albuminuria under AT1-receptor blockade - what is the potential role of aldosterone escape? Nephrol. Dial. Transplant 2007; 22: 5-8.
9. Goodfriend T.L., Ball D.L., Egan M.B. i wsp. Epoxy-ketoderivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358-363.
10. Fiebeler A., Muller D., Shagdarsuren E. i wsp. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2007; 16: 134-142.
11. Kokot F., Ficek R. Rola układu reninowo-angiotensyno-wo- aldosteronowego (RAA) w patogenezie nadciśnienia tȩtniczego. Postȩpy Nauk Medycznych 2002; 15: 117-122.
12. Cicoira M., Zanolla L., Rossi A. i wsp. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J. Am. Coll. Cardiol. 2001; 37: 1808-1812.
13. Nagata K., Obata K., Xu J. i wsp. Mineralocorticoid receptor antagonism attenuates cardiomyocyte hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 565-664.
14. Chrysostomou A., Pedagogos E., McGregor L. i wsp. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II-receptor blocker. Clin. J. Am. Soc. Nephrol. 2006; 1: 256-262.
15. Bianchi S., Bigazzi R., Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
16. Min L.J., Mogi M., Li J.M. i wsp. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 2005; 2: 433-442.
17. Nagai Y., Miyata K., Sun G.P. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK 1/2 in rat renal fibroblast. Hypertension 2005; 46 (2): 1039-1045.
18. Brown N.J., Nakamura S., Ma L. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000; 58: 1219-1227.
19. Rossi G.P., Bernini G., Dezideri G. i wsp. Renal damage in primary aldosteronism: Results of the PAPY study. Hypertension 2006; 48: 232-238.
20. Aldigier J.C., Kanjanbuch T., Ma L. i wsp. Regression of existing glomerulosclerosis by inhibition of aldosterone. J. Am. Soc. Nephrol. 2005; 16: 3306-3314.
21. Nakamura Y., Suzuki S., Suzuki T. i wsp. MDM2: A novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am. J. Path. 2006; 169: 362-371.
22. Fiebeler A., Nussberger J., Shagdarsuren E. i wsp. Aldosterone synthase inhibitor ameliorates angiotensin II - induced organ damage. Circulation 2005; 14: 3079-3094.
23. Ahokas R.A., Warrington K.J., Gerling I.C. i wsp. Aldo-steronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ. Res. 2003; 93: e124-e135.
24. Marumo T., Uchimura H., Hayashi M. i wsp. Aldosterone impairs bone marrow - derived progenitor cell formation. Hypertension 2006; 2: 490-496.
25. Chhokar V.S., Sun Y., Bhattacharya S.K. i wsp. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005; 111: 871-878.